Strides Pharma Q4 Results: Co still in the red, but loss narrows to Rs 14 crore
The US business reported a third consecutive quarter of over $60 million in revenues in Q4FY23, while other regulated markets recorded the highest quarterly sales of $48 million. The company attributed the US sales to new product introductions and solid base performance,
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
